AIM: To determine the frequency of GB virus C (GBV-C)/hepatitis G virus (HGV) infection before and after switch to the use of virus inactivated concentrates in haemophiliac patients infected with human immunodeficiency virus (HIV). PATIENTS AND METHODS: Initial and follow up sera from 49 children with haemophilia were analysed for the presence of GBV-C/HGV RNA and antibodies to HGV (anti-HGV). All patients had been infected with HIV while receiving concentrates without virus inactivation before 1984 and were subsequently treated with virus inactivated concentrates. RESULTS: In the first available serum sample (1987 or later), two of 49 patients were GBV-C/HGV RNA positive and two further patients were anti-HGV positive. During follow up (mean, 6 years), 14 patients developed markers of GBV-C/HGV infection. Eleven of these had received no blood products except clotting factor concentrates that had been prepared with virus inactivation. CONCLUSIONS: Despite being treated with virus inactivated clotting factor concentrates, HIV positive patients with haemophilia are at an increased risk of manifesting GBV-C/HGV infection. We hypothesise that GBV-C/HGV is transmitted by these clotting factor concentrates. However, we cannot rule out the emergence of markers of GBV-C/HGV infection as a result of the progression of immune impairment in the course of HIV infection.
AIM: To determine the frequency of GB virus C (GBV-C)/hepatitis G virus (HGV) infection before and after switch to the use of virus inactivated concentrates in haemophiliac patients infected with human immunodeficiency virus (HIV). PATIENTS AND METHODS: Initial and follow up sera from 49 children with haemophilia were analysed for the presence of GBV-C/HGV RNA and antibodies to HGV (anti-HGV). All patients had been infected with HIV while receiving concentrates without virus inactivation before 1984 and were subsequently treated with virus inactivated concentrates. RESULTS: In the first available serum sample (1987 or later), two of 49 patients were GBV-C/HGV RNA positive and two further patients were anti-HGV positive. During follow up (mean, 6 years), 14 patients developed markers of GBV-C/HGV infection. Eleven of these had received no blood products except clotting factor concentrates that had been prepared with virus inactivation. CONCLUSIONS: Despite being treated with virus inactivated clotting factor concentrates, HIV positive patients with haemophilia are at an increased risk of manifesting GBV-C/HGV infection. We hypothesise that GBV-C/HGV is transmitted by these clotting factor concentrates. However, we cannot rule out the emergence of markers of GBV-C/HGV infection as a result of the progression of immune impairment in the course of HIV infection.
Authors: T P Leary; A S Muerhoff; J N Simons; T J Pilot-Matias; J C Erker; M L Chalmers; G G Schlauder; G J Dawson; S M Desai; I K Mushahwar Journal: J Med Virol Date: 1996-01 Impact factor: 2.327
Authors: T Berg; U Naumann; T Fukumoto; W O Bechstein; P Neuhaus; H Lobeck; M Hohne; E Schreier; U Hopf Journal: Transplantation Date: 1996-09-27 Impact factor: 4.939
Authors: J Linnen; J Wages; Z Y Zhang-Keck; K E Fry; K Z Krawczynski; H Alter; E Koonin; M Gallagher; M Alter; S Hadziyannis; P Karayiannis; K Fung; Y Nakatsuji; J W Shih; L Young; M Piatak; C Hoover; J Fernandez; S Chen; J C Zou; T Morris; K C Hyams; S Ismay; J D Lifson; G Hess; S K Foung; H Thomas; D Bradley; H Margolis; J P Kim Journal: Science Date: 1996-01-26 Impact factor: 47.728